Microscopic observation showed that compared with mice in the BPD group, mice in the anti-IL-17A neutralizing antibody treatment group had significantly reduced pulmonary inflammation and improved alveolar destruction (Fig. 5), indicating that mice lacking IL-17 had improved pulmonary pathology. This evidence concerns the gene IL17A and bronchopulmonary dysplasia.